Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Herzog

Interventional Cardiology Columbia, MD Medical Doctor

NPI 1902873979 CMS profile 1298907

10710 Charter Dr, Suite 400, Columbia, MD 21044

Open in the dashboard

General payments

$2,228

99 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$952,078 paid to institutions, not to them · program years 2019–2023

Through program year 2023, William Herzog of Columbia, MD is reported in the CMS Open Payments database as having received $2,228 across 99 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $952,078 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 21st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $69 4
2022 General $601 33
2021 General $340 19
2020 General $191 11
2019 General $1,026 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Herzog
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to William Herzog were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year William Herzog Interventional Cardiology median Middle half National median
2019 $1,026 $1,097 $329–$3,048 $163
2020 $191 $473 $161–$1,480 $114
2021 $340 $677 $233–$1,827 $132
2022 $601 $978 $333–$2,724 $149
2023 $69 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Terumo Medical Corporation $599 6 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $282 14 payments
  3. Novartis Pharmaceuticals Corporation $228 15 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $204 11 payments
  5. AstraZeneca Pharmaceuticals LP $197 12 payments
  6. Merck Sharp & Dohme Corporation $111 7 payments
  7. Amgen Inc. $83 5 payments
  8. Chiesi USA, Inc. $71 3 payments
  9. Medtronic, Inc. $69 4 payments
  10. Janssen Pharmaceuticals, Inc $40 3 payments
  11. Other $344 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,656 95 payments
  2. Travel and Lodging $482 3 payments
  3. Education $90 1 payment
Products named General payments · program years 2019–2023
  1. Glidesheath $599 6 payments
  2. TR Band $599 6 payments
  3. Optitorque $572 4 payments
  4. Heartrail $572 4 payments
  5. JARDIANCE $267 13 payments
  6. ENTRESTO $228 15 payments
  7. LifeVest $204 11 payments
  8. BRILINTA $172 10 payments
  9. VERQUVO $111 7 payments
  10. Repatha $83 5 payments
  11. Other $702 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

32

Median for Cardiology: 2,533

Drug cost

$275

Median for Cardiology: $485,213

Branded share of claims

0%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 20 $202
Atorvastatin Calcium Generic 12 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$4,821

Medicare's payments for the services billed

Medicare patients

18

Average age 70

Services billed

25

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 61%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record